S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

AbbVie Inc.

ABBV · Healthcare · · USD
256.46 USD
0.00 (-1.44%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score HOLD Long-term (Investment)

58
/ 100
Technical 75
Trend & RS 78
Momentum 72
Fundamental 44
Macro 64
Liquidity 56
ComponentScoreWeight
Technical 75.0 10%
Trend & RS 77.5 10%
Momentum 72.5 5%
Fundamental 44.4 40%
Macro 64.4 15%
Liquidity 56.5 20%

Trade Setup

Entry 256.46
Stop Loss 245.08 (4.4%)
Target 1 (1:1) 267.84 (+4.4%)
Target 2 (2:1) 279.22 (+8.9%)
ATR(14) 5.69 (2.2%)
Risk per Share 11.38
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 0.0 -2.00
Momentum 72.5 +0.90
Quality 24.2 -1.03
Composite 32.2

Quality Scores

Piotroski F-Score 4 /9 — Average
✓ ✗ ✗ ✗ ✗ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 72.5 22.0 +229% above
P/B Ratio -76.3 4.0 Inline
Dividend Yield 2.7% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
61.81
vs
Market Price
256.46
Upside
-75.9%
Margin of Safety -314.9%
Stage 1 PV (5yr FCF)25,861,038,288
Terminal Value PV83,357,483,002
Total Enterprise Value109,218,521,290

Assumptions

Base FCF5,004,475,886
Growth Rate (5yr)10.2%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
37.84%
Full Kelly
18.92%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 58/100. Estimated win rate 57%, avg win 8.5%, avg loss 3.8%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
50.34
RSI(14)
2.3877
MACD

Relative Strength (RS) NEUTRAL

68
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY → FLAT (+9.0% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (27d since high)
Sector Outperformance +5.9% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
NEUTRAL: In line with the market — no strong outperformance or underperformance.

Technical Indicators

IndicatorValueSignal
Rsi 50.34 NEUTRAL
Macd 2.3877 BEARISH
Ma Cross 254.05 / 225.8 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 1.11x NORMAL

Key Levels

LevelPrice
52-Week High267.47
Bollinger Upper269.82
SMA(200)225.8
SMA(50)254.05
SMA(20)257.54
Current Price256.46
Bollinger Lower245.26
52-Week Low190.75
ATR(14)5.69

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.01x Normal bar — no special VSA pattern
2026-09-01 Normal 0.9x Normal bar — no special VSA pattern
2026-09-02 Normal 0.99x Normal bar — no special VSA pattern
2026-09-03 Normal 0.67x Normal bar — no special VSA pattern
2026-09-04 Normal 1.11x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 259.62 Above Kijun
Kijun-sen (26) 254.09 Base line
Senkou A 256.85 Leading span A
Senkou B 249.34 Leading span B
Cloud 249.34 – 256.85 Bullish (Green)
Price vs Cloud 256.46 Inside Cloud
Chikou Span 250.94 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 245.26 – 269.82  |  KC: 249.6 – 265.47

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 13

Anchored VWAP

VWAP: 236.54 Anchor: 2026-04-29 (52w Low) ABOVE AVWAP +8.4%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/ABBV

Valuation

MetricValue
Market Cap453.19B
P/E (TTM)72.45
Forward P/EN/A
P/B-76.35
EPS3.54

Financial Health

MetricValue
Revenue Growth10.2%
Profit Margin9.8%
ROEN/A
Debt/EquityN/A
Current Ratio0.81
Dividend Yield2.7%
Payout RatioN/A
Beta0.28

Trading Data

256.46
Open
256.46
Day High
256.46
Day Low
4.70M
Volume (0.7x avg)

Recent News (8)

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
MarketBeat · 2026-09-06
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
MarketWatch · 2026-09-05
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Motley Fool · 2026-09-05
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
Simply Wall St. · 2026-09-04
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 2026-09-04
Was JNJ Stock Rally Actually Its Own?
Trefis · 2026-09-04
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?
Zacks · 2026-09-04
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
Zacks · 2026-09-04

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —